Anonymous ID: 9cb02f June 10, 2021, 4:39 a.m. No.61779   🗄️.is 🔗kun   >>1780 >>1794 >>1814 >>1831 >>1858

>>61777

>wakes has the ball

G'Mornin' DigitZ Calls the BALL !o7

 

EU leaders urge unfettered probe into origins of COVID-19

https://www.reuters.com/business/healthcare-pharmaceuticals/eus-von-der-leyen-urges-unfettered-investigation-into-origins-covid-19-2021-06-10/

June 10, 2021 4:58 AM EDT 2 minute read

 

{pic caption }:

European Commission President Ursula von der Leyen speaks during a plenary session at the European Parliament

in Strasbourg, France June 9, 2021. Julien Warnand/Pool via REUTERS

 

EU leaders on Thursday called for an unfettered investigation into the origins of the COVID-19 pandemic, first identified in central China, amid criticism of an initial World Health Organization probe.

 

The WHO study in January and February was "insufficient and inconclusive", the U.S. mission to the U.N. in Geneva said in a statement last month, calling for what it called a timely, transparent and evidence-based second probe to be conducted, including in China.

 

"Investigators need complete access to whatever is necessary to really find the source of this pandemic," European Commission President Ursula von der Leyen told a news conference in Brussels.

 

The head of the European Council, Charles Michel, said: "The world has the right to know exactly what happened in order to be able to learn the lessons." He added that the EU supported all efforts.

 

A draft text to be approved at a EU-U.S. summit next week says: "We call for progress on a transparent, evidence-based and expert-led WHO-convened phase 2 study on the origins of COVID-19, that is free from interference." read more .

 

U.S. President Joe Biden in May said that U.S. intelligence agencies were pursuing rival theories potentially including the possibility of a laboratory accident in China.

 

The WHO report said the virus had probably been transmitted from bats to humans through another animal, and that "introduction through a laboratory incident was considered to be an extremely unlikely pathway".

 

EU diplomats have said the EU's support for a new study is mostly symbolic, as the bloc would not be directly involved read more .

 

The virus was first identified in the central Chinese city of Wuhan in late 2019.

 

>>61763 /lB NOTES Q-like post: Guess who's coming to dinner?

>FIRE > Flush?

Here Comes The FLUSH Fau Chi { Don't look here, LOOK there cards game or plumber ? }

>Hash Browns?

hash browns made by FRYing, the UK is Heating UP THIS FRYday with the G7 SUMMit STAGE

{ Gordon Brown was UK Prime Minister of Sinister{s} with Tony Blair }

 

COVID-19: Gordon Brown urges wealthiest nations to do more to help global vaccination effort

Posted on 06/07/2021

https://theoneworldnews.com/europe/covid-19-gordon-brown-urges-wealthiest-nations-to-do-more-to-help-global-vaccination-effort/

Anonymous ID: 9cb02f June 10, 2021, 5:30 a.m. No.61782   🗄️.is 🔗kun   >>1794 >>1798 >>1814 >>1858

COVID-19: Gordon Brown urges wealthiest nations to do more to help global vaccination effort

Posted on 06/07/2021

https://theoneworldnews.com/europe/covid-19-gordon-brown-urges-wealthiest-nations-to-do-more-to-help-global-vaccination-effort/

 

Former prime minister Gordon Brown has urged wealthier nations to do more to help vaccinate the entire world,

saying it is a decision of “who lives and who dies”.

 

Speaking to Sky News, the former Labour leader called on the leaders of the G7 nations, who are due to meet in Cornwall this weekend,

to put up the money needed to pay for vaccinations globally.

 

Mr Brown, a prominent anti-poverty campaigner, added that it is clear “we are not safe until everybody is safe" and also pressed

Prime Minister Boris Johnson to reverse the government’s proposed cut to foreign aid.

 

It comes as Conservative Party MPs hope to force Mr Johnson to reverse cuts to the foreign aid budget in a vote this afternoon.

Thirty Tories, including former prime minister Theresa May and four former cabinet ministers, are backing a rebellion against the £4bn reduction.

 

Mr Brown said: “It is pretty clear that we need to vaccinate the world. We are not safe until everybody is safe, as I have said.

 

“And it is an act of self-interest, it is not just an act of charity,

because if the disease spreads and mutates and comes back into our country through India, Nepal or Africa then we all suffer.

 

“So this is something that the world has got to do together and that is why on Friday

when Boris Johnson meets the G7 in Cornwall they’ve got the chance

– the richest countries sitting around the table

– they have got the chance to make a decision that will vaccinate the whole world

by putting up the money that is necessary to pay for it,

and sharing the doses that are excess in the United Kingdom.”

 

Mr Brown said the situation “needs a plan, not just a wing and a prayer”

and saidleftover{s}vaccine doses being handed over was “a good thing, but it is not enough”.

 

The former prime minister continued:

“I think you’ve got to look at these overseas aid cuts and think if you are pulling away the vaccine or the injection

needle from children and adults who need vaccinating and putting their lives at risk then that is not a good thing and there is not public support for that.

 

“And on Friday at the G7, we will decide, effectively, who lives and who dies

– who is to be vaccinated and is therefore safe and who is not to be vaccinated and is therefore at risk.”

 

The director-general of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus has previously said there is a “shocking imbalance”

in the global distribution of vaccines.

 

Mr Johnson will be hosting world leaders at the G7 summit in Carbis Bay, Cornwall, later this week

– and supporting the global recovery from the pandemic is likely to be a key topic on the agenda.

 

But pushed on the proposed foreign aid cut on Monday morning, solicitor general Lucy Frazer said it was

“important we support the effort” in the UK at this time in the pandemic.

 

Ms Frazer told Sky News that Chancellor Rishi Sunak could count on her vote on the matter as

“it is really important that we spend money at home at this time of the pandemic”.

 

/pB >>60306 sYm-baal-iZms

Anonymous ID: 9cb02f June 10, 2021, 6:16 a.m. No.61785   🗄️.is 🔗kun

>>61781

>/s

my thought also, even on initial sight of this >>61780

 

on

>>61763 /lB NOTES Q-like post: "4/4" { math says = ]WWG 1 WGA[ }

and

Scavino Tweet >>61669 /lB NHL Game / Anthem Rousing Cheers

at Start of VID at TOP RIGHT was the #44

 

QPost # 1468 (19) (10) has "/ 4"

Q !CbboFOtcZs 06/12/2018 13:20:15

...

(4) BOOMS Meme

...

From the summit document… 4 BOOMS

 

BOOM 1:The United States and the DPRK commit to establish new U.S.-DPRK relations

in accordance with the desire of the peoples of the two countries for peace and prosperity.

 

BOOM 2: The United States and the DPRK will join their efforts to build a lasting and stable peace

regime on the Korean Peninsula.

 

BOOM 3: Reaffirming the April 27, 2018 Panmunjom Declaration, the DPRK commits to work toward

complete denuclearization of the Korean Peninsula.

 

BOOM 4: The United States and the DPRK commit to recovering POW/MIA remains,

including the immediate repatriation of those already identified.

 

>>1714785

What a coincidence.

4 points / 4 booms

Dark to Light 1:07

More to come.

Q

Anonymous ID: 9cb02f June 10, 2021, 6:44 a.m. No.61787   🗄️.is 🔗kun   >>1814 >>1832 >>1833 >>1852 >>1858

17 comms ?!?

 

U.S. signs $1.2 bln deal for 1.7 mln courses of Merck's experimental COVID-19 drug

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-says-us-govt-buy-about-17-mln-courses-cos-covid-19-drug-2021-06-09/

June 9, 2021 9:17 AM EDT

3 minute read

 

Merck & Co Inc (MRK.N) said on Wednesday the U.S. government has agreed to pay about $1.2 billion for

1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.

 

The oral antiviral treatment, molnupiravir, aims to stop COVID-19 from progressing and can be given early in the course of the disease,

similar to Tamiflu to treat influenza.

 

The treatment course being tested in the trial is an oral dose given every 12 hours for five days.

 

Merck expects to have more than 10 million courses of the therapy available by the end of this year and said it was in discussions

with other countries interested in advance purchase agreements for molnupiravir.

 

The company, which is developing the drug with Ridgeback Biotherapeutics, is assessing the treatment in a late-stage trial

in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

 

Data from the trial, which plans to enroll a total of 1,850 patients globally, are expected in the fall of 2021,

according to the U.S. Department of Health and Human Services.

 

Other antiviral drugs also contending to be the first treatment aimed at the cause of COVID-19 include

Pfizer Inc's (PFE.N) PF-07321332 and Roche Holding AG's (ROG.S) AT-527. read more

 

If successful, Merck said it expects to file for the emergency use authorization of molnupiravir in the second half of 2021 at the earliest.

 

Merck has focused on its treatment after two COVID-19 vaccines it was developing failed to generate the necessary immune responses

in early testing, prompting it to abandon them in January.

 

The drugmaker announced a change of plans and said in April it would no longer pursue use of molnupiravir in hospitalized patients.

 

read more :

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-plans-large-outpatient-trial-covid-19-pill-stops-study-hospitalized-2021-04-15/

April 15, 2021 6:52 AM EDT

Anonymous ID: 9cb02f June 10, 2021, 7:20 a.m. No.61794   🗄️.is 🔗kun   >>1795 >>1814 >>1835 >>1858

>>61779, >>61782 { << LQQK HERE, NOT >>THERE>>, >>61779

>COVID-19: Gordon Brown urges wealthiest nations to do more to help global vaccination effort

 

U.S. to donate 500 million Pfizer doses to poor nations

June 10, 20218:56 AM EDT Andrea Shalal Steve Holland

3 minute read

 

The United States will spend $3.5 billion to buy and donate 500 million doses of the Pfizer (PFE.N) coronavirus vaccine

to some of the world’s poorest countries, it said on Thursday, urging other G7 nations to follow suit.

 

The vaccine donation - the largest ever by a single country - was announced before U.S. President Joe Biden meets

leaders of the Group of Seven advanced economies in western England.

 

The 500 million doses are destined for the world's 100 poorest countries.

A senior Biden administration official described the gesture as a "major step forward that will supercharge the global effort"

with the aim of "bringing hope to every corner of the world."

 

"We really want to underscore that this is fundamentally about a singular objective of saving lives," the official said,

adding that Washington was not seeking favours in exchange for the doses.

 

The Biden administration expects other G7 members to come up with contributions as part of a comprehensive road map

to end a pandemic that has killed more than 3.9 million people, the official added. read more

 

U.S. drug maker Pfizer and its German partner BioNTech (22UAy.DE) had earlier said they would provide 200 million doses

in 2021 and 300 million doses in the first half of 2022.

 

The shots, which will be produced at Pfizer's U.S. sites, will be supplied at a not-for-profit price.

 

"Our partnership with the U.S. government will help bring hundreds of millions of doses of our vaccine

to the poorest countries around the world as quickly as possible," said Pfizer Chief Executive Albert Bourla.

 

'DROP IN THE BUCKET'

 

Anti-poverty campaign group Oxfam called for more to be done to increase global production of vaccines.

 

"Surely, these 500 million vaccine doses are welcome as they will help more than 250 million people,

but that’s still a drop in the bucket compared to the need across the world,"

said Niko Lusiani, Oxfam America’s vaccine lead.

 

"We need a transformation toward more distributed vaccine manufacturing so that qualified producers worldwide

can produce billions more low-cost doses on their own terms, without intellectual property constraints," he added in a statement.

 

Biden has backed calls for a waiver of some vaccine intellectual property rights but there is no international consensus on how to proceed.

The new donations come on top of 80 million doses Washington has already pledged to donate by the end of June,

and $2 billion in funding earmarked for the COVAX program led by the World Health Organization (WHO)

and the Global Alliance for Vaccines and Immunization (GAVI), the White House said.

 

GAVI and the WHO welcomed the initiative.

 

Washington is also taking steps to support local production of COVID-19 vaccines in other countries,

including through its Quad initiative with Japan, India and Australia.

 

Biden’s announcement comes amid mounting pressure for the United States,

which has now given at least one shot to around 64% of its adult population,

to boost donations of vaccines to other countries in desperate need.

 

#Pfizer #DeathPenalty

Anonymous ID: 9cb02f June 10, 2021, 7:22 a.m. No.61795   🗄️.is 🔗kun   >>1814 >>1858

>>61794

>June 10, 20218:56 AM EDT Andrea Shalal Steve Holland

SAUCE:

https://www.reuters.com/business/healthcare-pharmaceuticals/biden-announce-donation-500-million-pfizer-doses-urge-others-join-2021-06-10/

Anonymous ID: 9cb02f June 10, 2021, 9:31 a.m. No.61852   🗄️.is 🔗kun   >>1858 >>1862

>>61832

>what large trial??

 

>>61833

>not use any of these afaik

 

{ would say this is FEARonMISSINGout (FOMO) market sQueeze Competition Game; like APOTEK'S HCQ Owner 187'd QPost# 2217 }

^^^^^ >>61838 >Trudope ^^^^^

 

moar deets in this article posted at last line

>>61787

>https://www.reuters.com/business/healthcare-pharmaceuticals/merck-plans-large-outpatient-trial-covid-19-pill-stops-study-hospitalized-2021-04-15/

>April 15, 2021 6:52 AM EDT

 

Merck & Co Inc (MRK.N) on Thursday said itplans a large study of what could become the first pill to target the coronavirus

in people at risk of severe COVID-19, but will no longer pursue use of the experimental antiviral drug in hospitalized patients.

 

The company said it would study the drug molnupiravir in a Phase 3 trial among COVID-19 patients out of hospitals

who have at least one risk factor for poor outcomes, such as advanced age, obesity or diabetes.

 

Trial participants can have had symptoms for no more than five days, shortened from seven days in a prior study.

 

"We had some encouraging signals in the outpatient trial. That was not the case in the inpatient trial,

but that was not unexpected," Roy Baynes, Merck's chief medical officer, told Reuters.

He said COVID-19 patients who need hospital treatment are often in the "inflammatory" phase of the disease,

which is too late for an antiviral drug to provide much help.

 

Molnupiravir, which Merck is developing with Ridgeback Biotherapeutics,

is designed to interfere with the ability of the coronavirus to replicate.

 

Merck also said it discontinued development of an experimental immune modulator, known as MK-7110,

for treating COVID-19 after concluding that clinical trial and manufacturing preparations would take too long.

 

The drug maker earlier this year stopped development of two COVID-19 vaccines,

citing data showing they were less effective than vaccines being developed by rivals.

 

Merck said its trials of molnupiravir found no drug-related adverse events that led participants to discontinue treatment

and there were no drug-related deaths.

 

Patients in the Phase 3 trial will be given 800 mg of molnupiravir twice a day for five days.

 

Merck said it plans to present at an upcoming medical meeting details from earlier studies of the drug in both hospitalized

and non-hospitalized patients. Results of the Phase 3 trial are expected by September or October, but interim analyses are planned.

 

Baynes said the company has ramped up production of molnupiravir and aims to have at least

10 million courses of therapy on hand later this year.

 

Merck also plans to study molnupiravir for preventing coronavirus infection in people exposed to the disease,

starting in the second half of the year.